Physician profile
Brittany Lamb
NPI 1750003778
$2,334.29
in general payments reported to CMS, 2019-2025
22 companies · $1,975 in 2025
The $1,975 reported for 2025 was more than what 98% of Registered Nurse providers received nationally (typical 2025 total: $73.55).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $359 · 2025: $1,975.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,334.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,334.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $403.89 | 2024-2025 | |
| Pfizer INC. | $345.34 | 2024-2025 | |
| Aucta Pharmaceuticals, INC. | $211.70 | 2024-2025 | Motpoly Xr |
| Neurocrine Biosciences, INC. | $206.32 | 2024-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $182.44 | 2025 | Symbravo |
| Ucb, INC. | $138.64 | 2024-2025 | Fintepla, Nayzilam |
| Sk Life Science, INC. | $104.45 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $100.62 | 2024-2025 | |
| Lundbeck LLC | $90.69 | 2025 | Vyepti, Rexulti |
| Otsuka America Pharmaceutical, INC. | $81.97 | 2024-2025 | Rexulti |
| Neurelis, INC. | $79.74 | 2024-2025 | Valtoco |
| Acadia Pharmaceuticals INC | $65.77 | 2025 | Nuplazid |
| Teva Pharmaceuticals USA, INC. | $56.11 | 2025 | Austedo Xr |
| Eisai INC. | $50.05 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $46.07 | 2025 | Wainua |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impel Pharmaceuticals LLC | $42.11 | 2025 | Trudhesa |
| Ge Healthcare | $26.49 | 2025 | |
| Scilex Pharmaceuticals INC. | $23.91 | 2024 | |
| Biogen, INC. | $22.44 | 2025 | Spinraza |
| Merz Pharmaceuticals, LLC | $21.40 | 2025 | Xeomin |
| Tonix Medicines, INC. | $20.96 | 2025 | Zembrace Symtouch |
| Takeda Pharmaceuticals U.S.A., INC. | $13.18 | 2024 | Hyqvia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittany Lamb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.